Notice of Results

RNS Number : 2533D

Tissue Regenix Group PLC

02 March 2022

 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Notice of Results

Investor Presentation

Tissue Regenix (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2021 on Tuesday 15 March 2022.

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 4.30pm on Tuesday 15 March 2022. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor  

Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.

For more information:

Tissue Regenix Group plc David Cocke, Chief Financial Officer	www.tissueregenix.com Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price / Nicholas Harland	Tel:  [phone]
Walbrook PR Ltd Alice Woodings / Lianne Cawthorne	Tel: [phone]  [e-mail]

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

NORDZGGFKMRGZZM